Prasugrel versus Clopidogrel for Acute Coronary Syndromes without Revascularization
New England Journal of Medicine2012Vol. 367(14), pp. 1297–1309
Citations Over TimeTop 1% of 2012 papers
Matthew T. Roe, Paul W. Armstrong, Keith A.A. Fox, Harvey D. White, Dorairaj Prabhakaran, Shaun G. Goodman, Jan H. Cornel, Deepak L. Bhatt, Peter Clemmensen, Felipe A. Martínez, Diego Ardissino, José Carlos Nicolau, William E. Boden, Paul A. Gurbel, Witold Rużyłło, Anthony J. Dalby, Darren K. McGuire, José L. Leiva-Pons, Alexander Parkhomenko, Shmuel Gottlieb, Gracita O. Topacio, Christian W. Hamm, Gregory Pavlides, Assen Goudev, Ali̇ Oto, Chuen‐Den Tseng, Béla Merkely, Vladimir Gašparović, Ramón Corbalán, Mircea Cintezǎ, R. Craig McLendon, Kenneth J. Winters, Eileen B. Brown, Yuliya Lokhnygina, Philip E. Aylward, Kurt Huber, Judith S. Hochman, E. Magnus Ohman
Abstract
Among patients with unstable angina or myocardial infarction without ST-segment elevation, prasugrel did not significantly reduce the frequency of the primary end point, as compared with clopidogrel, and similar risks of bleeding were observed. (Funded by Eli Lilly and Daiichi Sankyo; TRILOGY ACS ClinicalTrials.gov number, NCT00699998.).
Related Papers
- → Prasugrel compared with high-dose clopidogrel in acute coronary syndrome(2009)144 cited
- → Treatment Options for Patients With Poor Clopidogrel Response(2013)10 cited
- → Switching from Clopidogrel to Prasugrel in patients undergoing PCI: A meta-analytic overview(2015)6 cited
- → 1035(2012)
- Perspectives anarchistes sur la crise économique(2009)